Effects of OsteoStrong vs. Individually Adapted and Combined Training on Bone Health

Sponsor
Karolinska Institutet (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05721014
Collaborator
Region Stockholm (Other), The Swedish School of Sport and Health Sciences (Other), Linkoeping University (Other)
194
1
2
25.9
7.5

Study Details

Study Description

Brief Summary

The aim of this clinical trial is to investigate the effect of the OsteoStrong training method and the Individually Adapted and Combined Training on the bone health of older women with high fracture risk. Additionally, the aim is also to explore the participants' experiences of each training method.

Participants will be randomised to either treatment arm A (OsteoStrong) or treatment arm B (Individually Adapted and Combined Training). Participants in both groups will train for nine months. Treatment arm A will train individually once a week and treatment arm B will train in a group twice a week. Both groups will have a training instructor who will supervise and give training instructions.

Researchers will compare the groups to see the effects of the training methods on the participants' bone health among other outcome measures. The participants will be tested at baseline and post-intervention (9 months later).

Condition or Disease Intervention/Treatment Phase
  • Other: OsteoStrong
  • Other: Individually Adapted and Combined Physical Training
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
194 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of OsteoStrong vs. Individually Adapted and Combined Training on Bone Health Amongst Older Women With High Fracture Risk: A Randomised Controlled Trial
Actual Study Start Date :
Oct 4, 2021
Anticipated Primary Completion Date :
Jul 28, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: OsteoStrong

Training following the OsteoStrong-method.

Other: OsteoStrong
This training method is an isometric high-impact loading in four different training machines (Spectrum) and balance training on a vibration plate. The four machines are "chest press", "leg press", "pull-down" and "deadlift". The participants press and/or pull isometrically for around 30 seconds once on every machine. The training session takes around 20 minutes and is performed individually by the participants with the help of a training instructor.

Active Comparator: Individually Adapted and Combined Physical Training

Training based on current recommendations on exercise for people with osteoporosis.

Other: Individually Adapted and Combined Physical Training
This training method is based on the current recommendations on physical activity for people with osteoporosis. The training is individually adapted strength training combined with balance and weight-bearing exercises. The training is divided into two training sessions: Circuit training with ten stations with different exercises for the whole body (strength, balance, endurance, weight-bearing). The participants spend 40 seconds on each station. This is repeated during 40 minutes. The training session starts with a joint warm-up and ends with a cool-down. Strength training with machines for the whole body with the intensity of up to 70-80 % of one repetition max (1RM). The training session starts with a joint warm-up and and a voluntary individual cool-down. The training session takes around 60 minutes and is performed in a group with the help of a training instructor.

Outcome Measures

Primary Outcome Measures

  1. Bone Material Strength Index (BMSI) [Change from baseline at 9 months]

    Bone Material Strength Index measured with impact microindentation using OsteoProbe

Secondary Outcome Measures

  1. Bone Mineral Density (BMD) [Change from baseline at 9 months]

    Bone Mineral Density and T-score measured with Dual-Energy X-ray Absorptiometry (DXA)

  2. Procollagen Type 1 N-terminal propeptide (S-PINP) [Change from baseline at 3 and 9 months]

    Bone biomarker

  3. Serum C-telopeptide cross-link type 1 collagen (S-CTX) [Change from baseline at 3 and 9 months]

    Bone biomarker

  4. Sclerostin [Change from baseline at 3 and 9 months]

    Bone biomarker

  5. Bone alkaline phosphatase (S-BALP) [Change from baseline at 3 and 9 months]

    Bone biomarker

  6. Self-rated health questionnaire (SF-36) [Change from baseline at 9 months]

    A questionnaire with multiple choice questions about general health

  7. Falls Efficacy Scale (FES) [Change from baseline at 9 months]

    A questionnaire about self-efficacy and fear of falling, 1-10, where 0 equals "not sure at all" and 10 equals "completely sure". Higher scores equals better outcome.

  8. Socialstyrelsens questionnaire for lifestyle habits [Change from baseline at 9 months]

    A questionnaire with multiple choice questions about falls and fractures, physical activity, sitting, alcohol and smoking

  9. Numerical Rating Scale (NRS) [Change from baseline at 3 and 9 months]

    A pain rating scale from 0-10, where 0 equals "no pain" and 10 equals "maximum/worst possible pain imaginable". Higher scores equals worse outcome.

  10. Back extension strength [Change from baseline at 9 months]

    Measuring back extension strength with Digimax

  11. Grip strength [Change from baseline at 9 months]

    Measuring grip strength with hand dynamometer (JAMAR)

  12. Chair stand test [Change from baseline at 9 months]

    5 seconds, 30 seconds and time for making 50 chair stands

  13. Back extension endurance [Change from baseline at 9 months]

    Measuring back extension endurance with Sörensen's test

  14. Static sit-up [Change from baseline at 9 months]

    Sitting with the upper body in 45 degrees

  15. Lung capacity [Change from baseline at 9 months]

    Lung capacity measured with dynamic spirometry (Welch Allyn)

  16. One leg standing (eyes open) [Change from baseline at 9 months]

    Balance test

  17. One leg standing (eyes closed) [Change from baseline at 9 months]

    Balance test

  18. Two leg standing on a straight line (eyes open) [Change from baseline at 9 months]

    Balance test

  19. Two leg standing on a straight line (eyes closed) [Change from baseline at 9 months]

    Balance test

  20. Walking forward on a straight line [Change from baseline at 9 months]

    Balance test

  21. Walking backwards between to lines [Change from baseline at 9 months]

    Balance test

  22. BtrackS [Change from baseline at 9 months]

    Balance test, measuring body sway, standing on a platform with both legs together, arms crossed and eyes closed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 79 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Woman, 65-79 years old.

  • Vaccinated against Covid-19.

  • Be able to participate in nine months of training.

  • Untreated with Osteoporosis-medications, or have an ongoing treatment since at least one year back.

Exclusion Criteria:
  • Ongoing treatment with Osteoporosis-medications with an onset within a year, or a previous treatment which was terminated within the last five years.

  • Ongoing treatment with Osteoporosis-medications that has been delayed for more than eight months for Denosumab, or more than 18 months for bisphosphonates.

  • Vertebral fracture, that have been diagnosed within three months.

  • Vertebral fracture or hip fracture, that have not previously been treated with Osteoporosis-medications, or been assessed by a physician.

  • Bilateral hip replacements.

  • Symptomatic disc herniation, inguinal herniation or umbilical herniation.

  • Untreated hypertension.

  • Other diseases that can affect the results and participation in the study: malignant diseases, muscle dystrophy, secondary osteoporosis, or other conditions that would hinder study participation.

  • Ongoing treatment with oral cortisone pills (≥ 5 mg Prednisolone).

  • Conditions that hinders the conduction of impact microindentation with OsteoProbe: large edema, skin infection, allergy towards local anaesthetics.

  • Ongoing or previous training (within the last year) at OsteoStrong.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinska Institutet - Department of Neurobiology, Care Sciences and Society: Division of Family medicine and Primary care Huddinge Stockholms Län Sweden 141 52

Sponsors and Collaborators

  • Karolinska Institutet
  • Region Stockholm
  • The Swedish School of Sport and Health Sciences
  • Linkoeping University

Investigators

  • Principal Investigator: Helena Salminen, Ass. prof., Karolinska Institutet

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Helena Salminen, Associate professor, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT05721014
Other Study ID Numbers:
  • 2020-04359 Osteostrong
First Posted:
Feb 9, 2023
Last Update Posted:
Feb 9, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Helena Salminen, Associate professor, Karolinska Institutet
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2023